Treatment Strategies and Decision Making

Deciding when and how to treat Waldenström macroglobulinemia (WM) is a highly personalized process. Because WM is often a slow-growing condition, the goal of treatment is not necessarily to eliminate every lymphoma cell, but to control symptoms and protect your organs from the effects of the IgM protein ^[1][2].

The “Watch and Wait” Standard

If you have been diagnosed with WM but feel well and your blood counts are stable, your doctor will likely recommend active surveillance, also known as “watch and wait” ^[2].

It is important to understand that a high IgM level on its own is rarely a reason to start treatment ^[3]. While some patients with very high IgM levels (above 6,000 mg/dL) who have no symptoms may wait years before needing therapy, others can rapidly develop hyperviscosity ^[3]. Treatment usually only begins when the disease becomes “clinically significant,” meaning it causes ^[1][2]:

• Severe anemia (low red blood cells) or thrombocytopenia (low platelets) ^[1].
• Significant, symptomatic swelling of the lymph nodes, liver, or spleen ^[1].
• Emergencies like hyperviscosity syndrome (as covered on the Symptoms page) ^[4].
• Progressive, painful neuropathy (nerve damage) ^[1].
• Symptomatic cryoglobulinemia, cold agglutinin disease, amyloidosis, or kidney involvement.

Choosing a Treatment Path

When treatment is necessary, the decision typically falls into two main categories: fixed-duration chemoimmunotherapy or continuous BTK inhibitors, though clinical trials or other regimens may also be appropriate.

1. Fixed-Duration Chemoimmunotherapy

These treatments involve a combination of chemotherapy and an antibody drug (usually rituximab). They are typically given over about six months ^[5].

• Common Regimens: BR (Bendamustine-Rituximab) or DRC (Dexamethasone, Rituximab, Cyclophosphamide) ^[6][5].
• Pros: Treatment has a defined end date, allowing for a “treatment holiday.” It works well regardless of your genetic mutation status ^[7].
• Cons: Requires infusions at a clinic. Side effects can include prolonged cytopenias (low blood counts), elevated infection risk, infusion reactions, and significant immunosuppression ^[6][8].

2. Continuous BTK Inhibitors (BTKi)

These are targeted oral medications (pills) taken daily until the disease begins to grow again or side effects become too difficult ^[5].

• Common Drugs: Ibrutinib and Zanubrutinib ^[9].
• Zanubrutinib vs. Ibrutinib: In clinical trials, zanubrutinib was found to be just as effective as ibrutinib but with fewer “off-target” side effects, such as atrial fibrillation (irregular heartbeat), high blood pressure, and diarrhea ^[10][9].
• Pros: No needles or infusions; can be very effective at controlling the disease quickly ^[10].
• Cons: Must be taken every day indefinitely. BTK inhibitors carry specific risks including bleeding, atrial fibrillation, hypertension, and diarrhea. Do not stop a BTKi or alter your anticoagulants without speaking to your treating team ^[10].

How Genetics and Health Influence the Choice

Your doctor will look at your MYD88 and CXCR4 status (as covered on the Biology page) to guide this choice:

• MYD88-mutated: Responds very well to BTK inhibitors ^[11].
• CXCR4-mutated: May have a slower or less deep response to some BTK inhibitors; your doctor might prefer zanubrutinib or chemoimmunotherapy in these cases ^[12][13].
• MYD88-wild-type (no mutation): BTK inhibitors (especially ibrutinib) may be less effective; chemoimmunotherapy is often the preferred first choice ^[5][7].

Managing the “Rituximab Flare”

A unique risk with the drug rituximab is a sudden, temporary spike in IgM levels immediately after the first few doses, known as an IgM flare ^[14]. If your IgM is already very high (often over 4,000 mg/dL), this flare could push your blood into a dangerous state of hyperviscosity ^[15][16].

To prevent this, your doctor may:

1. Delay Rituximab: Start your other treatments first and wait to add the rituximab until your IgM levels have dropped safely ^[17].
2. Perform Plasmapheresis: In some cases, based on symptoms and serum viscosity, use a machine to temporarily remove the IgM from your blood (plasma exchange) before giving the rituximab ^[16][15]. (Note that this is not routine for everyone with high IgM and carries procedure-related risks).

Always ensure your team has a plan for managing your IgM levels if you are starting a rituximab-based treatment ^[1].